1 5 10

<210> 945
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 945
Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr
1 5 10

<210> 946
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, D amino acid residue

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 946
Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr
1 5 10

<210> 947
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 947
Phe Glu Trp Thr Val Pro Tyr Trp Gln Xaa Tyr
1 5 10

<210> 948
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa is acetylated phe

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 948
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 949
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa is acetylated phe

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 949
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 950
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=1-naphthylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 950
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 951
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 951
Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 952
<211> 11

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 952
Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 953
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 953
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 954
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 954
Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr

1 5 10

<210> 955
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 955
Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 956
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=naphthylalanine

<400> 956
Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met
1 5 10

<210> 957
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=naphthylalanine

<400> 957
Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr
1 5 10

<210> 958
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=naphthylalanine

<400> 958
Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 959
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=naphthylalanine

<400> 959
Asn Met Val Tyr Xaa Gln Pro Tyr Ser Ile Gln Thr
1 5 10

<210> 960
<211> 9

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 960
Val Tyr Trp Gln Pro Tyr Ser Val Gln
1 5

<210> 961
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 3, Xaa=naphthylalanine

<400> 961
Val Tyr Xaa Gln Pro Tyr Ser Val Gln
1 5

<210> 962
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 7, Xaa is an azetidine residue

<400> 962
Thr Phe Val Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 963
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, Xaa =p-benzoyl-L-phenylalanine

<400> 963
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 964
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa is an azetidine residue

<220>
<223> At position 11, Xaa=p-benzoyl-L-phenylalanine

<400> 964
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Xaa
1 5 10

<210> 965
<211> 11

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 8, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 965
Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 966
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 8, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 966
Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 967
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 7, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 967
Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10

<210> 968
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 7, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 968
Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10

<210> 969
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 3, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 969
Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 970
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 3, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 970
Phe Glu Xaa Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 971
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 971
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 972
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated p-benzoyl-L-phenylalanine

<220>
<223> At position 10, Xaa is an azetidine residue

<400> 972
Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 973
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 973
Val Tyr Trp Gln Pro Tyr Ser Val Gln
1 5

<210> 974
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 974
Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 975
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 5, Xaa=naphthylalanine

<400> 975
Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 976
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 976
Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 977
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 977
Arg Leu Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 978
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 978
Arg Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 979
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=D or Y

<220>
<223> At position 3, Xaa=D or S

<220>

<223> At position 4, Xaa=S, T or A

<220>
<223> At position 5, Xaa=S or W

<220>
<223> At position 6, Xaa=S or Y

<220>
<223> At position 7, Xaa=D, Q, E or V

<220>
<223> At position 8, Xaa=N, S, K, H or W

<220>
<223> At position 9, Xaa=F or L

<220>
<223> At position 10, Xaa=D, N, S or L

<220>
<223> At position 11, Xaa=L, I, Q, M or A

<400> 979
Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 980
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 980
Asp Asn Ser Ser Trp Tyr Asp Ser Phe Leu Leu
1 5 10

<210> 981
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 981
Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala
1 5 10

<210> 982
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 982
Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu
1 5 10

<210> 983
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 983
Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp
1 5 10 15

Cys

<210> 984
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 984
Thr Ser Glu Tyr Asp Asn Thr Thr Trp Tyr Glu Lys Phe Leu Ala Ser
1 5 10 15

Gln

<210> 985
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 985
Ser Gln Ile Pro Asp Asn Thr Ala Trp Tyr Gln Ser Phe Leu Leu His
1 5 10 15

Gly

<210> 986
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 986
Ser Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 987
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 987
Glu Gln Ile Tyr Asp Asn Thr Ala Trp Tyr Asp His Phe Leu Leu Ser
1 5 10 15

Tyr

<210> 988
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 988
Thr Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 989
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 989

Thr Tyr Thr Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Met Ser
1 5 10 15

Tyr

<210> 990
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 990
Thr Met Thr Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser
1 5 10 15

Tyr

<210> 991
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 991
Thr Ile Asp Asn Thr Ala Trp Tyr Ala Asn Leu Val Gln Thr Tyr Pro
1 5 10 15

Gln

<210> 992
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 992
Thr Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Ala Gln Tyr Pro
1 5 10 15

Asp

<210> 993
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 993
His Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr Tyr Thr
1 5 10 15

Pro

<210> 994
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 994
Ser Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser Tyr Lys
1 5 10 15

Ala

<210> 995
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 995
Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn
1 5 10 15

Ala

<210> 996
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 996
Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn
1 5 10 15

Thr

<210> 997
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 997

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Asn His Asn
1 5 10 15

Leu

<210> 998
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 998
His Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Gln Gln Gly Trp
1 5 10 15

His

<210> 999
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 999
Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1000
<211> 21
<212> PRT
<213> Artificial Sequence

372

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1000
Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1001
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1001
Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1002
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=phosphotyrosine

<220>
<223> At position 2, Xaa=naphthylalanine

<220>

<223> At position 3, Xaa=phosphotyrosine

<220>
<223> At position 5, Xaa is an azetidine residue

<400> 1002
Xaa Xaa Xaa Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 1003
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<400> 1003
Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1004
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1004
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1005

<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<400> 1005
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Ser
1 5 10 15

Asp Asn His

<210> 1006
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1006
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1007
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1007

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1008
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1008
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1009
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1009
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1010

<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1010
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1011
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST
PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1011
Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1012
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1012
Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1013
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1013
Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1014
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1014

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1015
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1015
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1016
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 10, Xaa=azetidine

<400> 1016
Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1017
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

PEPTIDE

<400> 1017
Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1018
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1018
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1019
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1019

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1020
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 10, Xaa=azetidine

<400> 1020
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1021
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa=azetidine

<400> 1021
Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1022
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa=azetidine

<400> 1022
Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr
1 5 10

<210> 1023
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST PEPTIDE

<220>
<223> At position 1, Xaa=acetylated phe

<220>
<223> At position 6, D amino acid residue

<220>
<223> At position 10, Xaa=azetidine

<400> 1023
Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1024
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1024
Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
1 5 10 15

Tyr Lys Gly Gly
20

<210> 1025
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1025
Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20

<210> 1026
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO-MIMETIC PEPTIDE

<400> 1026

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Leu Gly Gly
20

<210> 1027
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1027
Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
1 5 10

<210> 1028
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1028
Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 1029
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1029

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly Gly
20

<210> 1030
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1030
Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 1031
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST PEPTIDE

<400> 1031
Cys Asn Gly Arg Cys
1 5

<210> 1032
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TPO MIMETIC

<400> 1032
Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 1033
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1033
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Phe
20

<210> 1034
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1034
Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Phe
20 25

<210> 1035
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1035
Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 1036
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1036
Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 1037
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1037
Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 1038
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1038
Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
1 5 10 15

Arg Pro Ser Pro Lys Ala
20

<210> 1039
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC

<400> 1039
Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 1040
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC
PEPTIDE

<400> 1040
Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10

<210> 1041
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1041
Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 1042
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1042
Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly
1 5 10 15

Pro Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40

<210> 1043
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:EPO MIMETIC PEPTIDE

<400> 1043
Asp Leu Xaa Xaa Leu
1 5

<210> 1044
<211> 12
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:INTEGRIN BINDING PEPTIDE

<400> 1044
Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu
1 5 10

<210> 1045
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF ANTAGONIST

<400> 1045
Phe Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser
1 5 10 15

Leu Gly His Arg Pro
20

<210> 1046
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF ANTAGONIST

<400> 1046
Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly
1 5 10 15

Gly Gly Gly Gly Phe
20

<210> 1047
<211> 21

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

<400> 1047
Phe Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1048
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:IL-1 ANTAGONIST

<400> 1048
Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly
1 5 10 15

Gly Gly Gly Gly Phe
20

<210> 1049
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST

<400> 1049
Phe Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met
1 5 10 15

Trp Glu Trp Glu Cys Phe Glu Arg Leu
20 25

<210> 1050
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VEGF ANTAGONIST

<400> 1050
Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu Gly Gly Gly Gly Gly Phe
20 25

<210> 1051
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR

<400> 1051
Phe Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10 15

<210> 1052
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:MMP INHIBITOR

<400> 1052
Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly Phe
1 5 10 15

<210> 1053
<211> 10

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:INTEGRIN BINDING PEPTIDE

<400> 1053
Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr
1 5 10

<210> 1054
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:INTEGRIN BINDING PEPTIDE

<400> 1054
Arg Thr Asp Leu Asp Ser Leu Arg Thr
1 5

<210> 1055
<211> 757
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc-TNF-ALPHA INHIBITOR

<220>
<221> CDS
<222> (4)..(747)

<400> 1055
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc 48
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
1 5 10 15

ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

```
                    20                  25                  30

ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg   144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
                35                  40                  45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg   192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
        50                  55                  60

gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc   240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
    65                  70                  75

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg   288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
80                  85                  90                  95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc   336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
                100                 105                 110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca   384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
            115                 120                 125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag   432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
        130                 135                 140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc   480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
    145                 150                 155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg   528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
160                 165                 170                 175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc   576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
                180                 185                 190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc   624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
            195                 200                 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc   672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
```

```
        210                 215                 220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt gac ttc ctg ccg cac tac   720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr
    225                 230                 235

aaa aac acc tct ctg ggt cac cgt ccg taatggatcc                    757
Lys Asn Thr Ser Leu Gly His Arg Pro
240                 245
```

<210> 1056
<211> 248
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:Fc-TNF-ALPHA INHIBITOR

<400> 1056

```
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1               5                  10                  15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
            20                  25                  30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
        35                  40                  45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
    50                  55                  60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65                  70                  75                  80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
                85                  90                  95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
            100                 105                 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
        115                 120                 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
    130                 135                 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145                 150                 155                 160
```

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys
225 230 235 240

Asn Thr Ser Leu Gly His Arg Pro
245

<210> 1057
<211> 761
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:TNF-ALPH
INHIBITOR Fc

<220>
<221> CDS
<222> (4)..(747)

<400> 1057
cat atg gac ttc ctg ccg cac tac aaa aac acc tct ctg ggt cac cgt 48
Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg
1 5 10 15

ccg ggt gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca 96
Pro Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
20 25 30

gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa 144
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
35 40 45

ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 192

396

```
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
          50                  55                  60

gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac   240
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
     65                  70                  75

gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag   288
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 80                  85                  90                  95

cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac   336
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
                100                 105                 110

cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa   384
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
            115                 120                 125

gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag   432
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
        130                 135                 140

ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg   480
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
    145                 150                 155

acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc   528
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
160                 165                 170                 175

agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac   576
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
                180                 185                 190

tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc   624
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
            195                 200                 205

tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc   672
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
        210                 215                 220

ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag   720
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
    225                 230                 235

aag agc ctc tcc ctg tct ccg ggt aaa taatggatcc gcgg               761
```

Lys Ser Leu Ser Leu Ser Pro Gly Lys
240 245

<210> 1058
<211> 248
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:TNF-ALPH
INHIBITOR Fc

<400> 1058
Met Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro
1 5 10 15

Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
20 25 30

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
35 40 45

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
50 55 60

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

```
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
        195                 200                 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
    210                 215                 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225                 230                 235                 240

Ser Leu Ser Leu Ser Pro Gly Lys
                245
```

<210> 1059
<211> 763
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Fc IL-1
ANTAGONIST

<220>
<221> CDS
<222> (4)..(747)

<400> 1059

```
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc   48
    Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
      1               5                  10                  15

ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc   96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
                20                  25                  30

ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg   144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
            35                  40                  45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg   192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
        50                  55                  60

gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc   240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
    65                  70                  75
```

```
acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg   288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 80                  85                  90                  95

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc   336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
                100                 105                 110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca   384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
            115                 120                 125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag   432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
        130                 135                 140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc   480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
    145                 150                 155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg   528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
160                 165                 170                 175

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc   576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
                180                 185                 190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc   624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
            195                 200                 205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc   672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
        210                 215                 220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt ttc gaa tgg acc ccg ggt   720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly
    225                 230                 235

tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag             763
Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
240                 245
```

<210> 1060
<211> 248
<212> PRT